Autres langues Avenue Therapeutics, Inc.

Actions

ATXI

US05360L4032

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 01/05/2024			Varia. 5j.	Varia. 1 janv.
4,76 ^USD	-4,99%		-32,70%	-60,58%

18/03	Avenue Therapeutics, Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023	CI
22/02	Avenue Therapeutics, Inc. annonce la publication dans Drug Development Research de données précliniques de premier ordre sur BAER-101 dans un modèle translationnel d'épilepsie d'absence	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds	29/04
Avenue Therapeutics Announces Reverse Stock Split	24/04
Avenue Therapeutics to Host Virtual Key Opinion Leader Event on April 4, 2024	26/03
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024	25/03
Avenue Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights	18/03
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq	15/03
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting	11/03
Avenue Therapeutics Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in a Translational Model of Absence Epilepsy	22/02
Avenue Therapeutics, Inc. Announces Publication in Drug Development Research Highlighting First-In-Class Preclinical Data of BAER-101 in A Translational Model of Absence Epilepsy	22/02
Certain Stock Options of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	01/02
Certain Warrants of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	01/02
Certain Common Stock of Avenue Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-FEB-2024.	01/02
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference	11/01
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	05/01
Avenue Therapeutics Enters into Warrant Exercise Transactions for $5.0 Million in Proceeds	05/01
Top Midday Gainers	04/01
Avenue Therapeutics Shares Rise 68% After FDA Agreement for Tramadol Study	04/01
Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol	04/01
Avenue Therapeutics Announces Completion of Enrollment in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy	03/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Avenue Therapeutics, Inc.

Actions

ATXI

US05360L4032

Autres langues

Filtres